A malaria drug widely touted by President Donald Trump for treating the new coronavirus showed no benefit in a large analysis of its use in U.S. veterans hospitals. There were more deaths among those given hydroxychloroquine versus standard care, researchers reported.
The nationwide study was not a rigorous experiment. But with 368 patients, it’s the largest look so far at hydroxychloroquine with or without the antibiotic azithromycin for COVID-19, which has killed more than 171,000 people as of Tuesday.
Lauren Simpson, the policy director of Alliance for a Better Utah, voiced concerns about the purchase of the drugs.
“Aided by Senate President Adams, public funds will pay for a private gamble by Meds in Motion that could result in putting some Utahns’ health at risk,” Simpson said. “Medical professionals have expressed serious reservations with unsupervised, off-label use of anti-malarial drugs, and yet lawmakers are playing politics and bankrolling one individual’s speculative business decision at the risk of Utahns.”